Decision: Favourable
Study Title:
An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer
NREC Code:
23-NREC-MD-006
Decision:
Favourable
Meeting Date:
16/03/2023
Study Type:
MD Application
Principal Investigator:
Dr. Adrian Murphy
PI Institution:
Beaumont Hospital
Sponsor:
Seagen Inc.